# Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome

> **NCT02581865** · PHASE2 · COMPLETED · sponsor: **Neurocrine Biosciences** · enrollment: 124 (actual)

## Conditions studied

- Tourette Syndrome

## Interventions

- **DRUG:** NBI-98854
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02581865
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2020-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02581865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02581865, "Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02581865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*